Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 7(1): 4307, 2017 06 27.
Article in English | MEDLINE | ID: mdl-28655926

ABSTRACT

We examined the effect of chronic high fat diet (HFD) on amyloid deposition and cognition of 12-months old APP23 mice, and correlated the phenotype to brain transcriptome and lipidome. HFD significantly increased amyloid plaques and worsened cognitive performance compared to mice on normal diet (ND). RNA-seq results revealed that in HFD mice there was an increased expression of genes related to immune response, such as Trem2 and Tyrobp. We found a significant increase of TREM2 immunoreactivity in the cortex in response to HFD, most pronounced in female mice that correlated to the amyloid pathology. Down-regulated by HFD were genes related to neuron projections and synaptic transmission in agreement to the significantly deteriorated neurite morphology and cognition in these mice. To examine the effect of the diet on the brain lipidome, we performed Shotgun Lipidomics. While there was no difference in the total amounts of phospholipids of each class, we revealed that the levels of 24 lipid sub-species in the brain were significantly modulated by HFD. Network visualization of correlated lipids demonstrated overall imbalance with most prominent effect on cardiolipin molecular sub-species. This integrative approach demonstrates that HFD elicits a complex response at molecular, cellular and system levels in the CNS.


Subject(s)
Alzheimer Disease/etiology , Alzheimer Disease/metabolism , Brain/metabolism , Diet, High-Fat/adverse effects , Lipid Metabolism , Metabolome , Phenotype , Transcriptome , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/metabolism , Animals , Apoptosis , Brain/pathology , Cell Differentiation/genetics , Cognition , Computational Biology/methods , Disease Models, Animal , Female , Gene Expression Profiling , Maze Learning , Mice , Mice, Transgenic , Mitochondria/metabolism , Neurons/cytology , Neurons/metabolism , Plaque, Amyloid/pathology , Protein Aggregation, Pathological
2.
PLoS One ; 12(2): e0172161, 2017.
Article in English | MEDLINE | ID: mdl-28241068

ABSTRACT

ATP-binding cassette transporter A1 (ABCA1) controls cholesterol and phospholipid efflux to lipid-poor apolipoprotein E (APOE) and is transcriptionally controlled by Liver X receptors (LXRs) and Retinoic X Receptors (RXRs). In APP transgenic mice, lack of Abca1 increased Aß deposition and cognitive deficits. Abca1 haplo-deficiency in mice expressing human APOE isoforms, increased level of Aß oligomers and worsened memory deficits, preferentially in APOE4 mice. In contrast upregulation of Abca1 by LXR/RXR agonists significantly ameliorated pathological phenotype of those mice. The goal of this study was to examine the effect of LXR agonist T0901317 (T0) on the phenotype and brain transcriptome of APP/E3 and APP/E4 Abca1 haplo-deficient (APP/E3/Abca1+/- and APP/E4/Abca1+/-) mice. Our data demonstrate that activated LXRs/RXR ameliorated APOE4-driven pathological phenotype and significantly affected brain transcriptome. We show that in mice expressing either APOE isoform, T0 treatment increased mRNA level of genes known to affect brain APOE lipidation such as Abca1 and Abcg1. In both APP/E3/Abca1+/- and APP/E4/Abca1+/- mice, the application of LXR agonist significantly increased ABCA1 protein level accompanied by an increased APOE lipidation, and was associated with restoration of APOE4 cognitive deficits, reduced levels of Aß oligomers, but unchanged amyloid load. Finally, using Gene set enrichment analysis we show a significant APOE isoform specific response to LXR agonist treatment: Gene Ontology categories "Microtubule Based Process" and "Synapse Organization" were differentially affected in T0-treated APP/E4/Abca1+/- mice. Altogether, the results are suggesting that treatment of APP/E4/Abca1+/- mice with LXR agonist T0 ameliorates APOE4-induced AD-like pathology and therefore targeting the LXR-ABCA1-APOE regulatory axis could be effective as a potential therapeutic approach in AD patients, carriers of APOEε4.


Subject(s)
ATP Binding Cassette Transporter 1/genetics , Apolipoprotein E3/genetics , Apolipoprotein E4/genetics , Liver X Receptors/agonists , Transcriptome , Amyloid beta-Peptides/metabolism , Animals , Behavior, Animal , Brain/metabolism , Cluster Analysis , Fear , Female , Haploinsufficiency , Heterozygote , Humans , Male , Maze Learning , Memory Disorders/metabolism , Mice , Mice, Transgenic , Microtubules/metabolism , Phenotype , Software , Up-Regulation
3.
J Alzheimers Dis ; 56(3): 1075-1085, 2017.
Article in English | MEDLINE | ID: mdl-28106559

ABSTRACT

ATP-binding cassette transporter A1 (ABCA1) mediates cholesterol efflux to lipid-free apolipoproteins and regulates the generation of high density lipoproteins. Previously, we have shown that lack of Abca1 significantly increases amyloid deposition and cognitive deficits in Alzheimer's disease model mice expressing human amyloid-ß protein precursor (APP). The goal of this study was to determine if ABCA1 plays a role in memory deficits caused by amyloid-ß (Aß) oligomers and examine neurite architecture of pyramidal hippocampal neurons. Our results confirm previous findings that Abca1 deficiency significantly impairs spatial memory acquisition and retention in the Morris water maze and long-term memory in novel object recognition of APP transgenic mice at a stage of early amyloid pathology. Neither test demonstrated a significant difference between Abca1ko and wild-type (WT) mice. We also examined the effect of intra-hippocampal infused Aß oligomers on cognitive performance of Abca1ko mice, compared to control infusion of scrambled Aß peptide. Age-matched WT mice undergoing the same infusions were also used as controls. In this model system, we found a statistically significant difference between WT and Abca1ko mice infused with scrambled Aß, suggesting that Abca1ko mice are vulnerable to the effect of mild stresses. Moreover, examination of neurite architecture in the hippocampi revealed a significant decrease in neurite length, number of neurite segments, and branches in Abca1ko mice when compared to WT mice. We conclude that mice lacking ABCA1 have basal cognitive deficits that prevent them from coping with additional stressors, which is in part due to impairment of neurite morphology in the hippocampus.


Subject(s)
ATP Binding Cassette Transporter 1/deficiency , Cognition Disorders/metabolism , Cognition Disorders/pathology , Dendrites/metabolism , Dendrites/pathology , ATP Binding Cassette Transporter 1/genetics , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Animals , Cell Size , Female , Hippocampus/metabolism , Hippocampus/pathology , Humans , Male , Maze Learning/physiology , Mice, Inbred C57BL , Mice, Transgenic , Presenilin-1/genetics , Presenilin-1/metabolism , Recognition, Psychology/physiology , Spatial Memory/physiology
4.
Brain ; 138(Pt 12): 3699-715, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26510953

ABSTRACT

UNLABELLED: ATP binding cassette transporter A1 (encoded by ABCA1) regulates cholesterol efflux from cells to apolipoproteins A-I and E (ApoA-I and APOE; encoded by APOA1 and APOE, respectively) and the generation of high density lipoproteins. In Abca1 knockout mice (Abca1(ko)), high density lipoproteins and ApoA-I are virtually lacking, and total APOE and APOE-containing lipoproteins in brain substantially decreased. As the ε4 allele of APOE is the major genetic risk factor for late-onset Alzheimer's disease, ABCA1 role as a modifier of APOE lipidation is of significance for this disease. Reportedly, Abca1 deficiency in mice expressing human APP accelerates amyloid deposition and behaviour deficits. We used APP/PS1dE9 mice crossed to Apoe and Apoa1 knockout mice to generate Apoe/Apoa1 double-knockout mice. We hypothesized that Apoe/Apoa1 double-knockout mice would mimic the phenotype of APP/Abca1(ko) mice in regards to amyloid plaques and cognitive deficits. Amyloid pathology, peripheral lipoprotein metabolism, cognitive deficits and dendritic morphology of Apoe/Apoa1 double-knockout mice were compared to APP/Abca1(ko), APP/PS1dE9, and single Apoa1 and Apoe knockouts. Contrary to our prediction, the results demonstrate that double deletion of Apoe and Apoa1 ameliorated the amyloid pathology, including amyloid plaques and soluble amyloid. In double knockout mice we show that (125)I-amyloid-ß microinjected into the central nervous system cleared at a rate twice faster compared to Abca1 knockout mice. We tested the effect of Apoe, Apoa1 or Abca1 deficiency on spreading of exogenous amyloid-ß seeds injected into the brain of young pre-depositing APP mice. The results show that lack of Abca1 augments dissemination of exogenous amyloid significantly more than the lack of Apoe. In the periphery, Apoe/Apoa1 double-knockout mice exhibited substantial atherosclerosis and very high levels of low density lipoproteins compared to APP/PS1dE9 and APP/Abca1(ko). Plasma level of amyloid-ß42 measured at several time points for each mouse was significantly higher in Apoe/Apoa1 double-knockout then in APP/Abca1(ko) mice. This result demonstrates that mice with the lowest level of plasma lipoproteins, APP/Abca1(ko), have the lowest level of peripheral amyloid-ß. Unexpectedly, and independent of amyloid pathology, the deletion of both apolipoproteins worsened behaviour deficits of double knockout mice and their performance was undistinguishable from those of Abca1 knockout mice. Finally we observed that the dendritic complexity in the CA1 region of hippocampus but not in CA2 is significantly impaired by Apoe/Apoa1 double deletion as well as by lack of ABCA1. IN CONCLUSION: (i) plasma lipoproteins may affect amyloid-ß clearance from the brain by the 'peripheral sink' mechanism; and (ii) deficiency of brain APOE-containing lipoproteins is of significance for dendritic complexity and cognition.


Subject(s)
Amyloid beta-Protein Precursor/genetics , Apolipoprotein A-I/deficiency , Apolipoproteins E/deficiency , Cognition Disorders/genetics , Cognition Disorders/psychology , Gene Deletion , Plaque, Amyloid/genetics , ATP Binding Cassette Transporter 1/genetics , Amyloid beta-Peptides/administration & dosage , Amyloid beta-Peptides/blood , Amyloid beta-Peptides/metabolism , Amyloid beta-Peptides/pharmacokinetics , Amyloid beta-Protein Precursor/metabolism , Animals , Apolipoprotein A-I/genetics , Apolipoproteins E/genetics , Brain/metabolism , Brain/pathology , Cognition Disorders/pathology , Female , Hippocampus/metabolism , Lipoproteins/blood , Male , Mice , Mice, Knockout , Microinjections , Neurites/pathology , Peptide Fragments/administration & dosage , Peptide Fragments/blood , Peptide Fragments/metabolism , Peptide Fragments/pharmacokinetics , Plaque, Amyloid/pathology , Plaque, Amyloid/psychology
5.
J Alzheimers Dis ; 41(2): 535-49, 2014.
Article in English | MEDLINE | ID: mdl-24643138

ABSTRACT

Passive amyloid-ß (Aß) vaccination has shown significant effects on amyloid pathology in pre-depositing amyloid-ß protein precursor (AßPP) mice but the results in older mice are inconsistent. A therapeutic effect of LXR and RXR agonists consisting of improved memory deficits and Aß pathology has been demonstrated in different Alzheimer's disease (AD) mouse models. Here, we report the effect of a combination of N-terminal Aß antibody and synthetic LXR agonist T0901317 (T0) on AD-like phenotype of APP23 mice. To examine the therapeutic potential of this combination, the treatment of mice started at 11 months of age, when amyloid phenotype in this model is fully developed, and continued for 50 days. We show that Aß immunization with or without LXR agonist restored the performance of APP23 transgenic mice in two behavior paradigms without affecting the existing amyloid plaques. Importantly, we did not observe an increase of brain microhemorrhage which is considered a significant side effect of Aß vaccination. Target engagement was confirmed by increased Abca1 and ApoE protein level as well as increased ApoE lipidation in soluble brain extract. In interstitial fluid obtained by microdialysis, we demonstrate that immunization and T0 significantly reduced Aß levels, indicating an increased Aß clearance. We found no interaction between the immunotherapy and T0, suggesting no synergism, at least with these doses. The results of our study demonstrate that anti-Aß treatments can ameliorate cognitive deficits in AßPP mice with advanced AD-like phenotype in conjunction with a decrease of Aß in brain interstitium and increase of ApoE lipidation without affecting the existing amyloid plaques.


Subject(s)
Alzheimer Disease/therapy , Amyloid beta-Peptides/metabolism , Antibodies, Monoclonal/therapeutic use , Hydrocarbons, Fluorinated/therapeutic use , Immunization, Passive , Memory Disorders/therapy , Sulfonamides/therapeutic use , ATP Binding Cassette Transporter 1/metabolism , Amyloid beta-Protein Precursor/genetics , Amyloidogenic Proteins/immunology , Animals , Apolipoproteins E/metabolism , Brain/drug effects , Brain/pathology , Brain/physiopathology , Combined Modality Therapy , Conditioning, Psychological/drug effects , Conditioning, Psychological/physiology , Disease Models, Animal , Fear/drug effects , Fear/physiology , Female , Male , Maze Learning/drug effects , Maze Learning/physiology , Memory Disorders/pathology , Memory Disorders/physiopathology , Mice, Inbred C57BL , Mice, Transgenic , Nootropic Agents/therapeutic use , Random Allocation
SELECTION OF CITATIONS
SEARCH DETAIL
...